European startup funding rounds explained: what actually changes between a seed and a Series A
Ask ten founders in Berlin, Paris, or Stockholm what a Series A "is" and you'll get ten answers that don't quite match. That's the problem with European startup funding rounds explained in the abstract: everybody repeats the same ladder from the American blogs, and almost nobody accounts for the fact that a European seed is a different animal from a US seed. Same name. Different cash. Different expectations.
I've sat on both sides of this table — raising once, investing small cheques a few times since — and the single most common mistake I see is founders treating round labels as fixed milestones rather than as a market's shorthand for "how much risk are we still carrying?" Once you internalize that, the confusion mostly evaporates.
Key Takeaways
- A funding round is simply equity (or a convertible claim on it) exchanged for capital, tied to hitting the next proof point.
- European ticket sizes at each stage run meaningfully smaller than their US equivalents — often by a third or more.
- The instruments differ too: priced rounds, convertibles, and country-specific vehicles like BSA-AIR in France or ASA in Germany.
- Round labels are conventions, not rules. Two companies can both call themselves "seed" and be 18 months apart in maturity.
- Your equity percentage matters far less than the value of what you still own at the end. A smaller slice of a bigger, healthier company usually wins.
How do funding rounds work for startups?
Stripped to its bones, a round is a transaction: an investor hands over money, and in return receives a slice of your company or the right to convert into one later. What makes it a "round" rather than a one-off deal is that it's a bundle — several investors, one set of terms, one valuation, one closing date.
The money isn't the point in itself. Each round buys you runway to reach a specific proof point that makes the next round possible. That's the whole engine.
The proof-point logic
A pre-seed proves the team is worth backing. A seed proves people want the thing. A Series A proves the thing can be sold repeatedly and at a margin that doesn't collapse as you scale. Every stage is somebody asking: what have you removed from the risk column since last time?
Here's the thing most first-timers get wrong. They think the round is the goal. It isn't. The round is a tax you pay on the way to a milestone — dilution is the price, and you want to pay it as rarely and as cheaply as possible.
What you actually give up
Capital comes in two broad flavours. Equity is the standard: you sell shares, the investor owns a piece permanently. Venture debt is the alternative — a loan, usually layered on top of an equity round, cheaper in dilution terms but requiring repayment regardless of how things go.
A common European pattern: a modest equity round, then a venture-debt tranche a few months later to extend runway without another full raise. It works well when you have predictable revenue. It's a trap when you don't, because debt doesn't care about your roadmap.
What are the different types of startup funding rounds?
The ladder runs pre-seed, seed, Series A, B, and C, then growth rounds, then an exit. The letters are pure convention — Series A is the first "institutional" round, B is the second, and so on. Beyond C, the naming often abandons letters entirely and just says "growth" or "pre-IPO."
But the European ladder has its own rungs, and the ticket sizes are where it diverges most sharply from what you read on US blogs.
| Stage | Typical European ticket | What the investor wants to see |
|---|---|---|
| Pre-seed | €150k – €750k | A credible team and a plausible wedge |
| Seed | €1M – €4M | Early revenue, or a very strong usage signal |
| Series A | €4M – €15M | Repeatable sales, a real go-to-market motion |
| Series B | €15M – €50M | Efficient scaling, unit economics that hold |
| Series C and beyond | €50M+ | Market leadership, a path to an exit |
Those are ranges I've seen play out across several European ecosystems — treat them as orders of magnitude, not gospel. A Spanish seed and a Swiss seed can differ by a factor of three for reasons that have nothing to do with the company.
The instruments Europeans actually use
This is the part that trips up founders who've only read US guides. The SAFE — that simple, founder-friendly convertible instrument beloved in Silicon Valley — is far less standard here. Europe leans on a patchwork:
- Priced equity rounds — a full term sheet with a valuation, used from seed upward.
- Convertible notes — debt that converts at the next round, simpler but with a maturity date.
- BSA-AIR in France — a state-framed convertible that comes with tax advantages for the investor.
- ASA in Germany — a convertible loan structure that's become the default for many early German deals.
And then there's the subsidy layer, which is genuinely a European feature. France's Madelin framework gives investors income-tax relief for backing small companies. Germany's R&D credits reduce the cash cost of development. Belgium has its own early-stage incentive schemes. None of this exists in the US, and it materially changes who's willing to write a pre-seed cheque.
Why European tickets are smaller
The gap isn't just about ambition. European venture capital is a smaller pool, dominated by funds that are themselves smaller than their US peers. A fund with €80M under management can't write €5M seed cheques and still build a portfolio. So the whole supply chain shifts down.
The second reason is exit paths. A US founder can point to a hundred acquirers and a deep IPO market. A European founder is pointing at a thinner set of buyers and an IPO window that opens less often. Smaller exits justify smaller cheques.
What are the 7 stages of startup?
The seven-stage framing isn't a rule anyone enforces — it's a useful map. Here's how it usually breaks down:
- Ideation — no money, just a thesis.
- Validation — a handful of users, no revenue, often still self-funded.
- Pre-seed — first outside capital, team still forming.
- Seed — you have a product and a signal that people want it.
- Series A — a repeatable sales motion exists and you're hiring around it.
- Series B and beyond — scaling the machine, professionalizing operations.
- Exit — acquisition, IPO, or, increasingly, staying private and profitable.
The trap in this list is that the boundaries are soft. I've seen companies raise a €3M seed with exactly the traction another company called a Series A. The label is a negotiation, not a fact.
Why the stages are fuzzier than the list suggests
Post-2021, the appetite for growth-at-all-costs cooled. Investors started asking harder questions about capital efficiency and paths to actual profit. That shift blurred the stage boundaries further — a seed round now often expects what a Series A expected a few years earlier.
Which is honestly healthier. The old model of burning through letters for the sake of the next letter produced a lot of companies with impressive cap tables and no business.
Is 1% equity in a start-up good?
This one comes up constantly among early hires and angel investors. The honest answer: 1% is neither good nor bad in isolation. It depends entirely on what you own it in, when you got it, and what happens next.
1% of a company that sells for €50M is €500,000. 1% of a company that dies is zero. The percentage is a claim on a numerator you can't yet see.
The math that matters
Suppose you take a smaller equity stake to avoid a round that would crush you. A founder holding 15% of a thriving company is far better off than one holding 40% of a company that can't raise because the valuation is unrealistic. Dilution is only painful when the thing you're diluting is actually worth something.
The other variable is vesting and structure. 1% in restricted stock with a four-year vest and a cliff is not the same as 1% in options with a strike price set at today's valuation. Check the terms, not just the number.
If you're an early hire, my blunt view: any single-digit percentage that isn't tied to a real exit path is worth less than the salary you gave up. Ask about the liquidation preferences. Ask what happens in a modest acquisition. Founders get precious about this question, and the ones who won't answer it clearly are telling you something.
What changed after the 2021 bubble
European venture went through a genuine reset after the 2021 peak. The funding frenzy cooled, valuations corrected, and the bar for a Series A went up. Investors who'd written cheques on a deck now wanted cohort retention data.
The aggregate numbers recovered, but the composition shifted. A larger share of capital is going to companies that can show a credible path to profitability, and a smaller share to the pure-growth plays that defined the boom years. That's not a bad thing if you're building something real.
What it means practically: if you're raising in 2026, expect a longer process and a more skeptical room than founders did four years ago. Budget six months for a Series A, not three. And expect at least one investor to ask why you're not just bootstrapping to profitability.
Reading European rounds like an insider
The labels — pre-seed, seed, Series A — are a shared language, not a taxonomy. Once you understand that a European round is a smaller, differently-instrumented, subsidy-influenced version of its American cousin, the whole picture sharpens.
Here's what I'd leave you with. The founders who navigate this well aren't the ones who chase the biggest headline valuation. They're the ones who treat each round as a tool for removing a specific risk, who take only as much dilution as the milestone requires, and who understand that in Europe, the subsidy layer and the instrument you choose matter as much as the number on the term sheet.
The round you raise is not the achievement. It's the fuel. What you do with the next eighteen months is the achievement — and nobody puts that in a press release.
